Indication
Gastrointestinal Neuroendocrine Tumors
2 clinical trials
2 products
1 drug
Clinical trial
Phase I/II Trial of Systemic Targeted Radioligand Therapy (TRT) With Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR Positive (SSTR+) Gastrointestinal (GI) Neuroendocrine Tumors (NET) and Pheochromocytoma/Paragangliomas Previously Treated With Systemic Radioligand TherapyStatus: Not yet recruiting, Estimated PCD: 2029-07-01
Drug
68Ga-DOTATATEProduct
[203Pb]VMT-alpha-NETProduct
[212Pb]VMT-alpha-NETClinical trial
Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck CancersStatus: Not yet recruiting, Estimated PCD: 2029-01-01